C9466 — Injection, benralizumab, 1 mg
C9466 is a HCPCS Level II code for injection, benralizumab, 1 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on December 31, 2018 and is not valid on new claims.
This code has been terminated
CMS terminated C9466 on December 31, 2018. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9466
- Long descriptor
- Injection, benralizumab, 1 mg
- Short descriptor
- Injection, benralizumab
- Added
- April 1, 2018
- Terminated
- December 31, 2018
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9466
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9466 is not quite right, the correct code is very often within a few positions of it.
- C9458Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuriesterminated
- C9459Flutemetamol f18, diagnostic, per study dose, up to 5 millicuriesterminated
- C9460Injection, cangrelor, 1 mg
- C9461Choline c 11, diagnostic, per study doseterminated
- C9462Injection, delafloxacin, 1 mg
- C9463Injection, aprepitant, 1 mgterminated
- C9464Injection, rolapitant, 0.5 mgterminated
- C9465Hyaluronan or derivative, durolane, for intra-articular injection, per doseterminated
- C9467Injection, rituximab and hyaluronidase, 10 mgterminated
- C9468Injection, factor ix (antihemophilic factor, recombinant), glycopegylated, rebinyn, 1 i.u.terminated
- C9469Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mgterminated
- C9470Injection, aripiprazole lauroxil, 1 mgterminated
- C9471Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mgterminated
- C9472Injection, talimogene laherparepvec, 1 million plaque forming units (pfu)terminated
- C9473Injection, mepolizumab, 1 mgterminated
- C9474Injection, irinotecan liposome, 1 mgterminated
Questions about C9466
What is HCPCS code C9466?
C9466 is a HCPCS Level II code for injection, benralizumab, 1 mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9466?
The CMS HCPCS file marks C9466 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9466 still valid?
No. C9466 was terminated on December 31, 2018 and should not be used on new claims.